United States
H.R. 3029
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
The bill would require the National Institute of Standards and Technology (NIST) to develop best practices and technical standards for nucleic acid synthesis—the process of creating custom DNA and RNA used in medicines and agricultural products—to address biosecurity risks from potential misuse. It would direct NIST to conduct research on screening, operational security, and related topics, convene industry and stakeholder groups to establish consensus priorities, and advance safety standards for engineering biology and biomanufacturing, including risks from artificial intelligence.[AI-Generated]
Record as of 21 July 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.
- 21 July 2026 Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
- 20 July 2026 Passed House with amendment
4 more actions
- 20 July 2026 Motion to reconsider laid on the table Agreed to without objection.
- 20 July 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 3029.
- 20 July 2026 Considered under suspension of the rules. (consideration: CR H4666-4667)
- 20 July 2026 Mr. Babin moved to suspend the rules and pass the bill, as amended.
- 16 July 2026 Reported by committee
- 16 July 2026 Placed on calendar (House)
2 more actions
- 29 April 2025 Ordered to be Reported by Voice Vote.
- 29 April 2025 Committee Consideration and Mark-up Session Held
- 28 April 2025 Referred to committee
- 28 April 2025 Introduced in House
Read the live feed — on the site or in the app Look up H.R. 3029 on Congress.gov All US bills